Ally Bridge Group (Ny) LLC Fate Therapeutics Inc Transaction History

Ally Bridge Group (Ny) LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $2.63 Million - $5.33 Million	-88,500 Reduced 32.78%	181,500 $7.04 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $721,600 - $1.17 Million	10,000 Added 3.85%	270,000 $22.3 Million
Q4 2020 Feb 16, 2021	BUY	$38.09 - $100.95 $9.9 Million - $26.2 Million	260,000 New	260,000 $23.6 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Ally Bridge Group (Ny) LLC, based on Form 13F filings with the SEC.

Stay updated on Ally Bridge Group (Ny) LLC with notifications on news.